Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

medicalstarn 424 posts  |  Last Activity: Aug 8, 2013 1:41 PM Member since: Apr 1, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • IntelGenx (IGXT :$0.60) – Drug Delivery company focused on Oral method with strong pipeline of pharma drugs

    Targets: Near term: $2 – $3 /// Long term: $5+

    6th August, 2013

    New HOT Stock pick: IntelGenx Corp. (IGXT: $0.60)

    IntelGenx has an FDA approved drug (Fortivo XL) on the market and several in pipeline for various indications with multi billion dollar market for some of the other approved drugs on the market for the treatments. Company has many good partnerships in place with companies like PAR Pharma, RedHill BioPharma, Edgemont Pharmaceuticals and others.
    IntelGenx is uniquely positioned to capture a huge marketshare given its large portfolio of patents in Drug Delivery Systems. It has 3 key methods:
    1) VersaTab – Controlled release tablets
    2) VersaFilm – Rapidly disintegrating film
    3) AdVersa – Mucoadhesive tablet

    Company has NO debt and has sufficient cash for near term giving its current burn rate.
    Current capital structure includes:

    Shares outstanding: 58 Million
    Insider Ownership: 22%

    --

  • IntelGenx (IGXT :$0.60) – Drug Delivery company focused on Oral method with strong pipeline of pharma drugs

    Targets: Near term: $2 – $3 /// Long term: $5+

    6th August, 2013

    New HOT Stock pick: IntelGenx Corp. (IGXT: $0.60)

    IntelGenx has an FDA approved drug (Fortivo XL) on the market and several in pipeline for various indications with multi billion dollar market for some of the other approved drugs on the market for the treatments. Company has many good partnerships in place with companies like PAR Pharma, RedHill BioPharma, Edgemont Pharmaceuticals and others.
    IntelGenx is uniquely positioned to capture a huge marketshare given its large portfolio of patents in Drug Delivery Systems. It has 3 key methods:
    1) VersaTab – Controlled release tablets
    2) VersaFilm – Rapidly disintegrating film
    3) AdVersa – Mucoadhesive tablet

    Company has NO debt and has sufficient cash for near term giving its current burn rate.
    Current capital structure includes:

    Shares outstanding: 58 Million
    Insider Ownership: 22%

    -.-

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    df

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    df

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dfb

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    df

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dsf

  • medicalstarn by medicalstarn Aug 7, 2013 12:08 PM Flag

    dsf

  • medicalstarn by medicalstarn Aug 7, 2013 12:07 PM Flag

    dfd

  • medicalstarn by medicalstarn Aug 7, 2013 12:07 PM Flag

    dfbdf

  • medicalstarn by medicalstarn Aug 7, 2013 12:07 PM Flag

    df

  • Unknown Gem with Brutal Upside Potential.... Thank me later

    2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow in the next 6 months .

    IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
    According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.

    IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
    According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.

    Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

    Intelgenx (IGXT)

    Market Cap : $30 M
    Cash: $3 M
    Price:0.60

    Burn-Rate : $1.5 M a year
    Shares Out : 51 M ( 30 M shares are held by Investors )

    IGXT´s Monster Pipeline :

    Product ......Application......... Status of Development

    INT0004/2006 Antidepressant -- US launch in 4Q 2012

    INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014

    INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014

    INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014

    INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA

    INT0020/2010 Insomnia -- in Pivotal Study

    INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

    INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

    INT0030/2011 Animal health -- in Pivotal Study

    INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study

    ---

  • Unknown Gem with Brutal Upside Potential....

    2 Big Drugs already under review by FDA another 1 NDA filing for Potency Drug and 1 ANDA filing for CHF will follow in the next 6 months .

    IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
    According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.

    IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
    According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.

    Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

    Intelgenx (IGXT)

    Market Cap : $30 M
    Cash: $3 M
    Price:0.60

    Burn-Rate : $1.5 M a year
    Shares Out : 51 M ( 30 M shares are held by Investors )

    IGXT´s Monster Pipeline :

    Product ......Application......... Status of Development

    INT0004/2006 Antidepressant -- US launch in 4Q 2012

    INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014

    INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014

    INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014

    INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA

    INT0020/2010 Insomnia -- in Pivotal Study

    INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

    INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

    INT0030/2011 Animal health -- in Pivotal Study

    INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study

    --

  • Unknown Gem with Brutal Upside Potential....

    2 Big Drugs already under review by FDA another 1 NDA filing for Potency Drug and 1 ANDA filing for CHF will follow in the next 6 months .

    IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
    According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.

    IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
    According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.

    Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

    Intelgenx (IGXT)

    Market Cap : $29 M
    Cash: $3 M
    Price:0.57

    Burn-Rate : $1.5 M a year
    Shares Out : 51 M ( 30 M shares are held by Investors )

    IGXT´s Monster Pipeline :

    Product ......Application......... Status of Development

    INT0004/2006 Antidepressant -- US launch in 4Q 2012

    INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014

    INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014

    INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014

    INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA

    INT0020/2010 Insomnia -- in Pivotal Study

    INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

    INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

    INT0030/2011 Animal health -- in Pivotal Study

    INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study

    --